KRAS and non-small cell lung carcinoma: Compared to tons of EGFR inhibitors studied as ABCB1 reversal agents, MRTX849 showed good anticancer efficacy and safety in patients with non-small cell lung cancer and colorectal cancer with KRAS G12C mutation in clinical studies[49, 57].